Needham & Company Maintains a 'Strong Buy' on Par Pharmaceutical (PRX); Zuplenz Approval Adds Another Product to Strativa Product Portfolio
Tweet Send to a Friend
Needham & Company maintains a 'Strong Buy' on Par Pharmaceutical (NYSE: PRX), PT $36.
Needham analyst says, "PRX’s branded division ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says, "PRX’s branded division ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
